Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of anti-thymocyte globulin in recent-onset type 1 diabetes
2019-003265-17Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing ATG 2.5 mg/kg with Placebo (2 arms). Started Jul 2020; status: completed.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2019-003265-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003265-17.